



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/16, 9/20, 9/28 A61K 9/50	A1	(11) International Publication Number: WO 92/09270 (43) International Publication Date: 11 June 1992 (11.06.92)
(21) International Application Number: PCT/GB91/02057 (22) International Filing Date: 21 November 1991 (21.11.91) (30) Priority data: 9025372.5 22 November 1990 (22.11.90) GB (71) Applicant (for all designated States except US): BRITISH TECHNOLOGY GROUP PLC [GB/GB]; 101 Newington Causeway, London SE1 6BU (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): NEWTON, John, Michael [GB/GB]; 16 Britten House, Britten Street, London SW3 3UB (GB). (74) Agent: HAMILTON, Raymond; Patents Department, British Technology Group plc, 101 Newington Causeway, London SE1 6BU (GB).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU ⁺ , US. Published <i>With international search report.</i>
(54) Title: CONTROLLED RELEASE COMPOSITIONS (57) Abstract A controlled release composition comprising an extruded core of active material and excipients, said core being coated in a water insoluble coating. Preferably the core comprises a pharmaceutically acceptable active together with microcrystalline cellulose, a clay such as kaolin and a binder such as poly(vinylpyrrolidone).		

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

CONTROLLED RELEASE COMPOSITIONS

This invention relates to extruded controlled release compositions.

The majority of solid oral dosage forms used in the pharmaceutical industry are produced by the compression of powders or granulated powders. The extrusion of wet powder masses has been utilised as a preliminary step in forming the granulate into a useful dosage form but in these cases the extrudate must be subjected to a further processing step. The manufacture of useful dosage forms as the direct product of an extrusion process remains a desirable objective in the art.

We have discovered that a wet mixture of an active material and excipient can be extruded to produce an extruded core having a smooth surface, which when coated in a water insoluble coating will retain its structural integrity upon exposure to an aqueous medium. The coated extruded compositions provide a controlled release of active material, i.e. when exposed to an aqueous medium the active is released into that medium over a prolonged period. Such coated extruded cores are believed to be novel and thus, from one aspect this invention provides a controlled release composition comprising an extruded core of active material and excipients, said core being coated in a water insoluble coating.

The present invention is of broad applicability in the formulation of active substances, particularly biologically active substances. Examples of classes of biologically active materials which may be incorporated in the compositions of the invention include pharmaceuticals, bacteriostats, viruscides, insecticides, herbicides, larvicides, fungicides, algacides and nematocides. The compositions of this invention find wide application in medicine including veterinary medicine and in horticulture and agriculture as well as outside these areas. The area of particular interest is that of pharmaceutical dosage forms for human or animal use. The preferred compositions of this invention comprise excipients which are pharmacologically

- 2 -

acceptable and the invention will be described with particular reference to those preferred embodiments. It will be appreciated that in relation to other embodiments, the use of other materials as excipients may be possible or even preferred.

05 The wet powder comprising the active and the excipient and also any additional components must be one which is capable of being extruded to form a coherent extrudate. The extrudate preferably has a smooth surface at least on its exterior faces. The composition of the wet mass may need to be adjusted in order
10 to facilitate the production of such preferred extrudates. The nature of the extrudate varies with the proportions of the components of the wet mass and the nature of those components. For any particular active material the nature of and proportions of the remaining components of the wet mass can be adjusted until
15 an acceptable extrudate is formed.

 Preferably the excipient comprises microcrystalline cellulose. Microcrystalline cellulose materials useful in the compositions of this invention include all those pharmacologically acceptable non-dispersable cellulose
20 derivatives which are known to be useful in the art of tablet formation from wet powder granulates. Examples include all those products sold under the Trade Marks AVICEL and EMCOCEL by the FMC Corporation and Forum Chemicals respectively.

 Furthermore, the excipients may include a clay. Clays useful
25 in the compositions of this invention include all those pharmacologically acceptable clays known in the art particularly the kaolinities, montmorillonites, bentonites and attapulgites. The preferred clays are kaolin and bentonite.

 Preferred excipients comprise from 25-75% by weight
30 microcrystalline cellulose and from 75-25% by weight of clay. Preferably the proportion of microcrystalline cellulose (hereinafter for convenience termed "MCC") to clay is approximately equal, i.e. the ratio of the weight of MCC to clay is preferably within the range 1:1 \pm 20% and more preferably 1:1
35 \pm 5%.

- 3 -

Certain grades of commercially available materials sold as microcrystalline cellulose contain minor proportions of other ingredients, e.g. other cellulose derivatives such as carboxymethyl cellulose. Such materials are useful in the compositions of this invention.

The compositions of the present invention preferably comprise at least one pharmaceutically active material.

This material should be one which is not susceptible to significant degradation under the conditions employed to extrude the wet mass. The pharmaceutically active compounds which may usefully be incorporated into the compositions of this invention include all those which may be formulated as tablets by a wet granulation process. The range of active compounds is thereby a wide one and indeed any active which is not significantly degraded by exposure to an aqueous environment in the form of the wet powder mixture or by the conditions employed during the extrusion process or in processing the extrudate especially in drying it may be utilised. Examples of active materials which may be utilised include β blockers such as atenolol and metoprolol; calcium antagonists such as nifedipine and nitrendipine, ACE inhibitors such as enalapril and captopril; β_2 agonists such as salbutamol and terbutaline, hormones, for example androgenic, estrogenic and progestational hormones, notably steroids such as oestradiol, sympathomimetic agents, hypoglycaemic agents, contraceptives, nutritional agents, peptides and proteins, nitrates such as isorbide dinitrate, mononitrate and GTN; xanthines such as theophylline; NSAID's such as piroxicam and diclofenac; benzodiazepines such as triazolam and zopiclone; α blockers such as prazosine and alfuzosine; antivirals such as acyclovir, zidovudine and ampliten, cephalosporins such as cefaclor, antispasmodics such as alverine and salicylates such as 5 amino salicylic acid, preparations containing analgesics, for example aspirin. Mixtures of active substances may be incorporated into the controlled release device.

- 4 -

The proportion of the pharmaceutically active material which is incorporated may vary between wide limits, say from 1.0 to 20% by weight of the total weight of the excipients, up to as much as 50%, or even 80% by weight in the case of actives which do not adversely affect the nature of the extruded core. In particular, the amount of active which may be incorporated may detract from the ability of the core to retain its structural integrity in an aqueous medium. The maximum quantity of any particular active which can be incorporated may be determined empirically.

The wet mass which is to be extruded to form the core of the compositions of this invention will normally be wetted with water. However, it may be wetted with non-aqueous liquids and this may be preferable for example where the active material is water sensitive or where the active is not soluble in water to a degree which facilitates the formation of the extrudate. A variety of non-aqueous solvents may be utilised and in the preferred embodiments these will be pharmacologically acceptable organic solvents. Examples of non-aqueous solvents which may be used include the lower alcohols especially ethanol and hydrocarbons such as mineral oils and paraffin oils. Where these non-aqueous solvents are utilised, the excipient must be organophilic. A preferred group of organophilic excipients are the clays as described above.

The amount of liquid which is added to the dry components will be such as to render the matter mass susceptible to extrusion. The amount may vary within wide limits but in general quantities of from 20 or 40% to 60% of the total weight of the dry ingredients may be utilised.

Particular examples of water sensitive drugs include acetyl salicylic acid (asprin), procaine, cocaine, physostigmine, tetracaine, methyl dopate, dibukucaine, ergotamine benzylpenicillin sodium, chloramphenicol, nitrozezan, chlordiaze-poxide, penicillins and cephalosporins. Other active materials which may advantageously be used in the processes of this

- 5 -

invention include water soluble vitamins, bronchodilators such as salbutamol, highly deliquescent compounds such as potassium chloride. Further water-sensitive active materials include water soluble materials that form highly viscous solutions when
05 dissolved in water. Examples of such materials are the sugars, including sucrose, dextrose, fructose and hydrophobic polymers.

In a preferred embodiment the excipient includes a water soluble polymeric binder such as poly(vinylpyrrolidone (PVP), gelatin, acacia or starch. Such a binder is conveniently
10 incorporated by utilising an aqueous solution thereof to wet the dry ingredients. Generally the use of a dilute solution containing from 0.5% to 10% by weight of binder will be suitable. The use of such a binder exerts an advantageous effect upon the mechanical properties of the extruded core.

15 The dry powder mixtures of this invention may comprise a minor proportion generally not more than 20% by weight and preferably not more than 10% by weight of other conventional powder excipients. The weight of such additional excipients may be equal to but will not normally exceed the combined weight of
20 the MCC and the clay. Examples of such excipients include calcium carbonate, barium sulphate, lactose, starch and the carboxymethylcelluloses etc. The presence of these additional excipients may exert a deleterious effect upon the properties of the extruded product and the proportions of such excipients which
25 are employed should preferably be adjusted so as to keep these deleterious effects within acceptable limits.

The wet mass is formed into the core of the controlled release dosage form by extrusion through a die. The nature of the die will influence the shape and hence the release
30 characteristics of the extruded core. For example, the active wet mass can be extruded through circular, elliptical or annular dies. Thus, the extruded cores may be circular or annular in cross-section, i.e. rods or hollow tubes. Typically such rods or tubes will have an external diameter of from 1mm to 20mm,
35 preferably from 2mm to 8mm, and in the case of the hollow tubes

- 6 -

an internal diameter of from $\frac{1}{2}$ mm to 10mm. The extruded lengths of material may be cut into appropriate lengths to produce the dosage forms. The geometrical dimensions of such rods and tubes will, of course, be dependent on the use of the rod or tube.

05 Thus, for use in humans the tubes or rods will be of a size suitable for swallowing, whereas for animal use they may be correspondingly larger. Suitable lengths for tubes or rods for human use is from 5 to 20mm.

The extrusion process may be carried out using equipment and techniques which are known in the art of extrusion processing. Examples of extrusion equipment which may be utilised include end plate extruders, screen extruders, rotary cylinder extruders, rotary gear extruders and ram extruders. The operating parameters of the extruder will be adjusted so as to optimise the properties of the extrudate in accordance with techniques which are familiar to those skilled in the art of extrusion. Thus, for example the rate and temperature of the materials to be extruded and the pressure to which they are subjected may need to be adjusted in order to produce a useful extrudate.

15

20 By appropriate adjustment to the force applied to cause extrusion and if necessary to the composition of the mixture, it should be possible to obtain an extrudate under steady-state flow conditions which has an acceptably smooth surface. The speed of extrusion may vary but those formulations which can be extruded relatively rapidly say at least 5m min^{-1} are preferred for present use.

25

The extrudates are normally dried prior to their being incorporated into the controlled release devices of the present invention. However, it is possible to incorporate them into such a device prior to their being dried as hereinafter described.

30

In order that the extrudates retain their structural integrity during the period over which the active material is to

- 7 -

be released, it is necessary that they be coated with a water insoluble material. Such a coating may extend over the entire surface of the extrudate provided that it is sufficiently water permeable to facilitate the release of the active material.

05 However, usually the coating will extend over the majority of the surface area of the extrudate leaving an area uncoated or coated with a permeable material through which the active material is released. Where a portion of the surface of the extrudate is uncoated at least some of the active may be released by erosion

10 of the core. However, in the preferred embodiments, the amount of erosion will be relatively small and certainly less than will compromise the integrity of the device. In the case of the rod shaped or other elongated extrudates, the extrudate may conveniently be coated prior to being chopped into smaller

15 pieces. The cut ends of the chopped rods are left uncoated and the active is released wholly or partially through these uncoated areas. In a similar manner the hollow tubes can be coated and chopped to produce dosage forms in which the cut ends and interior surfaces of the tube are uncoated or coated in a

20 permeable material, and release may take place through these areas.

Processes for the production of these controlled release forms are believed to be novel and form a second aspect of this invention. The invention provides a process for the production

25 of a controlled release composition which comprises extruding a wet mass of active material and excipient and coating the extrudate so as to preserve its structural integrity in an aqueous medium.

The extrudates may be and preferably are chopped into pieces

30 prior to drying. The pieces may be subjected to further processing steps. The dry extrudates typically have a density of from 1.5 to 3.0 gm/cc.

The coated extruded cores will retain their structural integrity for a period after ingestion. Both the geometric form

35 and nature of the coating will influence the delayed release

characteristics. Thus, cores of a hollow cylindrical form may have their outer exterior surface coated in a water insoluble material and the inner exterior surface uncoated, or coated in a water soluble or water permeable material. In either variation, dissolution of the active material will principally occur from the interior surface and proceed in a controlled manner. The nature and area of application of the coating is such as to retain the structural integrity of the composition, whilst permitting a controlled release of active.

Suitable water insoluble coatings include ethyl cellulose, polymethyl-methacrylate and aqueous dispersions thereof. Suitable permeable coatings include cellulose derivatives such as hydroxypropyl-methylcellulose and methylcellulose. Additionally plasticizers may be included in the coating such as polyethylene glycol (PEG), glycerol and its esters and phthalate esters. Such coatings are known in pharmaceutical technology and thus any comparable coating that will retain the structural integrity of the extruded core may be used.

Furthermore, the invention includes extruded cores that are hollow tubes wherein the hollow centre is filled by a second pharmaceutically acceptable material. Preferably the second pharmaceutically acceptable material is co-extruded with the extruded core. In such a case the interior extruded form may be of the kind of the present invention or of any other extrudable kind.

A cylindrical extruded core of the present invention may be co-extruded with a second pharmaceutically acceptable material such as the core fills the hollow centre of the second active material. In such a case the coating may be applied to the exterior surface of the co-extrudate, or the co-extrudate may act as a coating in itself.

The extruded forms may form the core of a layered tablet. They may be inserted into a capsule either singly or in numbers. Where a number of forms are enclosed in a capsule they may be identical or different. In some applications it may be

- 9 -

convenient to co-extrude a coating onto the extruded wet dosage form.

The invention is illustrated by the following Examples:

EXAMPLE 1

05 Preparation of Extruded Cores

A dry powder mix was formed by introducing the ingredients listed below into a planetary mixer (Kenwood) and mixing for five minutes. The fluid medium, either purified water or a 5% w/v solution of poly(vinyl pyrrolidone) was introduced and the mixing
10 continued for ten minutes. The resulting wet mixture was inserted into the barrel of a ram extruder having a barrel of diameter 2.54cm fitted with a specially designed annular die. The ram was attached to the cross-head and driven at a rate of 100 mm/min.

15 Using different annular dies, tubular extruded cores were obtained of different external:internal diameter ratios (E/I). The annular die was replaced by a circular one to produce rods. The tubes and rods were cut to the lengths stated.

The extrudates were dried by being placed in an oven
20 overnight at 55-60°C. They were cut into lengths 5, 10, 15 and 20mm and trimmed by scalpel. The permeable coating used comprised PEG4000 20-60% w/w and ethylcellulose (EC) N50 2.5-5% w/v dissolved in equal parts of methylene chloride and methanol. The non-permeable coating comprised N50 (EC) 5% w/v in the
25 methylene chloride methanol solvent. Coating was performed using an Aeromatic AG Stream 1 fluidised bed coater (ACM Machinery, Tady) and operated under the following optimised conditions in all coating processes:

	Atomised air pressure	0.4 bar
30	Feed rate of coating dispersion	5 G/M
	Fluidisation air (fan capacity)	9 units
	Inlet temperature	50°C
	Drying temperature	50°C
	Drying time	30 minutes

- 10 -

The following ingredients in grams were used to prepare tubular extruded cores of theophylline. The percentage theophylline content is given at the bottom of the table.

Code	R1	R2	R3	R4
Avicel PH 101	50	50	50	50
Kaolin light	50	50	50	50
Calcium carbonate	90	60	25	-
PVP (5% w/v in water)	90	90	90	90
Theophylline (anhydrous)	10	50	75	100
% Theophylline content	4.89	23.3	36.6	48.9

05 The following ingredients in grams were used to prepare rods and tubular extruded cores of riboflavin.

Code	R5	R6	R7	R8	R9	R10	R11	R12
Avicel PH 101	25	25	25	25	25	25	25*	25*
Kaolin light	25	25	25	25	25	25	-	-
Riboflavin	5	5	5	5	5	5	5	5
PVP (5% w/v in water)	-	42	-	40	-	45	-	-
Barium sulphate	45	45	-	-	-	-	70	70
Lactose	-	-	45	45	-	-	-	40
Calcium carbonate	-	-	-	-	45	45	-	-
Water	36	-	35	-	40	-	38	-

* Avicel PH 101 replaced by Avicel PH 581, a grade of microcrystalline cellulose which contains sodium carboxymethyl cellulose.

EXAMPLE 2

10 Controlled Release by Extruded Cores

Dissolution Study of Film Coated Cores

A. The in-vitro theophylline release of coated tubular extrudate was determined using the paddle unit (method 2) of USPXXI dissolution test apparatus (model PTWS, Pharma Test Apparatebau, W. Germany). All these tests were conducted in 900ml of
 15 dissolution medium maintained at $37.0 \pm 0.5^\circ\text{C}$ with paddle rotation speed of 100 RPM. Sample of 3ml volume were withdrawn

- 11 -

at various predetermined time intervals using an automated sampler (Pharma Test Apparatebau Type PTFC1, W. Germany). The drug concentration of the samples was determined by direct measurement of the UV absorbance at 272nm using a Perkin, Elmer
05 554 UV-Vis spectrophotometer after appropriate dilution if high drug concentration were used. The tubes were resting in horizontal position on the bottom of the dissolution vessels during the dissolution tests. Each of the samples below were incubated in this system under the conditions stated. In all
10 Figures the ordinate shows % release of drug and the abscissa time in hours.

1. Theophylline tubes: Permeable external surface coat, no internal coating.

Core codes: R2 to R4 (E/I = 8/4, length 15mm)

15 Samples were taken over a period of 18 hours. Figure 1 shows a controlled pattern of release over this time. R2 identified by (■), R3 (▲) and R4 (●).

2. Theophylline tubes: Impermeable external coat, no internal coat.

20 Core codes: R1 (E/I = 8/4, length 15mm).

The dissolution medium was replaced by (a) phosphate buffer (■), (b) 0.1N HCl (●), (c) distilled water (+). Figure 2 shows the release profile over a 15 hour period.

3. Theophylline tubes: External and internal permeable coating.

25 Core codes: R1 to R4 (E/I = 8/4, length 5mm).

Figure 3 shows the release profile over 15 hours (R1 ♦, R2 ■, R3 ▲, R4 ●).

Figure 4 shows R1 in different dissolution media (a) phosphate buffer (■), (b) 0.1N HCl (●), (c) distilled water (+).

30

4. Theophylline tubes: Permeable external coat, no internal coat.

Core code: R1 (E/I = 4/2, length 10mm).

- 12 -

Figure 5 shows the release profile over 15 hours, in the different dissolution media as described above (a), (b) and (c).

- 05 5. Theophylline tubes: Permeable external coat, no internal coat.

Core code: R1 (E/I = 8/4, length 15mm).

Figure 6 shows the effect of a 2.5% (▲) and 3.19% (◆) coating on these tubes. (% coating taken as the % by weight of the coated tube).

- 10 6. Theophylline tubes: Impermeable external coat, no internal coat.

Core code: R1 (E/I = 8/4).

Figure 7 shows R1 tubes of length 5mm (■), 10mm (▲), 15mm (●) and 20mm (◆).

- 15 B. The in-vitro release of riboflavin containing extruded tubes and rods was determined using a simulated stomach/intestine model. This model was the paddle unit as described above. The extruded cores are exposed to a simulated gastric fluid (pepsin in 0.1N HCl) for 3 hours, followed by 3 hours in simulated
20 intestinal fluid (pancreatin in 0.2M phosphate buffer). In Figure 8 the ordinate shows % riboflavin released and the abscissa time in hours.

1. Riboflavin rods (diameter 5mm) and tubes (external diameter 3mm, internal diameter 2mm). All length 15mm: Coating
25 ECN50, PEG-70%, diethylphthalate 20%.

Core codes: R8 (■), R6 (+), R10 (●), all tubes.

R8 (◆) and R6 (▲), rods.

Figure 8 shows the release profile over 6 hours. The cores are identified as shown above.

- 13 -

CLAIMS

1. A controlled release composition comprising an extruded core of active material and excipients, said core being coated with a water insoluble material.
2. A controlled release composition according to claim 1,
05 characterised in that the active material is a pharmaceutical.
3. A composition according to claim 2, characterised in that the excipient is a pharmacologically acceptable material.
4. A composition according to claim 3, characterised in that the excipient comprises microcrystalline cellulose.
- 10 5. A composition according to claims 1 to 4, characterised in that the excipient comprises a clay.
6. A composition according to claim 5, characterised in that the clay selected from the group comprising kaolinites, montmorillonates, bentonites and attapulgites.
- 15 7. A composition according to claim 5, characterised in that the clay is selected from the group comprising kaolin or bentonite.
8. A composition according to any of the preceding claims, characterised in that the excipient comprises from 25-75% by weight of microcrystalline cellulose and from 75-25% by weight of
20 a clay.
9. A composition according to claim 8, characterised in that the ratio of the weight of microcrystalline cellulose to the weight of clay is within the range $1:1 \pm 20$.
10. A composition according any of the preceding claims,
25 characterised in that the active material comprises from 1.0 to 80% by weight of the weight of the total weight of excipient.
11. A composition according to any of the preceding claims, characterised in that the composition includes a binder selected from the group consisting of poly(vinylpyrrolidone), acacia,
30 gelatine and starch.
12. A composition according to claim 11, characterised in that the binder is poly(vinylpyrrolidone).
13. A composition according to any of the preceding claims,

- 14 -

characterised in that the excipient includes any of the ingredients selected from the group comprising calcium carbonate, barium sulphate, lactose, starch and carboxymethyl cellulose.

05 14. A composition according to any of the preceding claims, characterised in that the core has a circular cross section.

15. A composition according to claim 14, characterised in that the core is hollow.

16. A composition according to claim 15, characterised in that the core has an annular cross section.

10 17. A composition according to any of claims 14 to 16, characterised in that the core has an external diameter of from 2mm to 8mm.

15 18. A composition according to either of claims 16 to 17, characterised in that the core has an internal diameter of from 1mm to 4mm.

19. A composition according to any of the preceding claims, characterised in that the composition is from 5 to 20mm in length.

20 20. A composition according to any of the preceding claims, characterised in that the majority of the surface of the core is coated with an insoluble coating.

21. A composition according to any of claims 1 to 20, characterised in that at least a portion of the surface of the core is coated with a permeable material.

25 22. A composition according to claim 21, characterised in that the entire surface of the core is coated with a permeable material.

23. A composition substantially as hereinbefore described with reference to the foregoing examples.

30 24. A process for the preparation of a controlled release composition, characterised in that a wet mass comprising active material and excipient is extruded through a die and the extrudate is coated with a water insoluble material.

25. A process according to claim 24, characterised in that the die is circular.

35 26. A process according to claim 24, characterised in that the

- 15 -

die is annular.

27. A process according to any of claims 24 to 26, characterised in that the extrudate is dried and subsequently coated.

05 28. A process according to claim 27, characterised in that the dried extrudate is coated with a water insoluble coating.

29. A process according to claim 26, characterised in that the outer exterior surface of the extrudate is coated with a water insoluble coating.

10 30. A process according to claim 26, characterised in that the outer exterior surface is coated with a water insoluble coating and the inner surface is coated in a water permeable coating.

31. A process according to claim 26, characterised in that the entire surface of the extrudate is coated with a permeable material.

15 32. A process for the preparation of a controlled release composition substantially as hereinbefore described with reference to the foregoing examples.

1 / 4




Fig.1




Fig.2




Fig.3

2/4




Fig.4




Fig.5

3/4




Fig.6




Fig.7

4/4




Fig.8

INTERNATIONAL SEARCH REPC T

International Application No

PCT/GB 91/02057

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	A 61 K 9/16	A 61 K 9/20 A 61 K 9/28
A 61 K 9/50		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	GB,A,2190287 (BIREX) 18 November 1987, see claims 1-8,14-16; page 1, lines 50-62	1-8,10, 13,20, 24,27, 28
Y	EP,A,0249949 (WARNER-LAMBERT) 23 December 1987, see claims 1,3-6,11; page 3, lines 9-12,33-39; page 4, lines 3-12; page 4, example	1-8,10, 13,20, 24,27, 28
Y	GB,A,2170104 (WARNER-LAMBERT) 30 July 1986, see claims 1,3,7; page 2, lines 4-22,34,35; page 3, example I	1-8,10, 13,20, 24,27, 28
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
18-02-1992	16.03.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Maria Peis <i>Maria Peis</i>	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9102057

SA 53479

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 10/03/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2190287	18-11-87	ZA-A- 8703373	03-11-87
EP-A- 0249949	23-12-87	US-A- 4810501	07-03-89
		AU-B- 611085	06-06-91
		AU-A- 7419687	24-12-87
		JP-A- 63258406	25-10-88
		ZA-A- 8703851	25-11-87
GB-A- 2170104	30-07-86	US-A- 4600645	15-07-86
		AU-A- 5261886	07-08-86
		BE-A- 904137	29-07-86
		CH-A- 668705	31-01-89
		DE-A- 3601002	31-07-86
		FR-A- 2576514	01-08-86
		GB-A- 2170210	30-07-86
		JP-A- 61176536	08-08-86
		LU-A- 86273	09-06-86
		NL-A- 8600210	18-08-86
		SE-A- 8600377	31-07-86
		US-A- 4912146	27-03-90
		AU-B- 583582	04-05-89
		AU-A- 5261986	07-08-86
		BE-A- 904136	29-07-86
		CA-A- 1270760	26-06-90
		CH-A- 667008	15-09-88
		DE-A- 3601001	07-08-86
		FR-A- 2576786	08-08-86
		JP-A- 61176521	08-08-86
		LU-A- 86274	09-06-86
		NL-A- 8600194	18-08-86
		SE-A- 8600402	01-08-86